RT Journal Article
SR Electronic
T1 Microneedle-mediated gene delivery for the treatment of ischemic myocardial disease
JF Science Advances
JO Sci Adv
FD American Association for the Advancement of Science
SP eaaz3621
DO 10.1126/sciadv.aaz3621
VO 6
IS 25
A1 Shi, Hongpeng
A1 Xue, Tong
A1 Yang, Yang
A1 Jiang, Chenyu
A1 Huang, Shixing
A1 Yang, Qi
A1 Lei, Dong
A1 You, Zhengwei
A1 Jin, Tuo
A1 Wu, Fei
A1 Zhao, Qiang
A1 Ye, Xiaofeng
YR 2020
UL http://advances.sciencemag.org/content/6/25/eaaz3621.abstract
AB Cardiovascular disorders are still the primary cause of mortality worldwide. Although intramyocardial injection can effectively deliver agents to the myocardium, this approach is limited because of its restriction to needle-mediated injection and the minor retention of agents in the myocardium. Here, we engineered phase-transition microneedles (MNs) coated with adeno-associated virus (AAV) and achieved homogeneous distribution of AAV delivery. Bioluminescence imaging revealed the successful delivery and transfection of AAV-luciferase. AAV–green fluorescent protein–transfected cardiomyocytes were homogeneously distributed on postoperative day 28. AAV–vascular endothelial growth factor (VEGF)–loaded MNs improved heart function by enhancing VEGF expression, promoting functional angiogenesis, and activating the Akt signaling pathway. The results indicated the superiority of MNs over direct muscle injection. Consequently, MNs might emerge as a promising tool with great versatility for delivering various agents to treat ischemic myocardial disease.